Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumorsEMBO REPORTSIF6.22024-12-110OA
A Senescence-Mimicking (Senomimetic) VEGFR TKI Side Effect Primes Tumor Immune Responses via IFN/STING SignalingMOLECULAR CANCER THERAPEUTICSIF5.52024-04-300PRE